TCGA-D8-A73X-01A-11R-A32P-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 26
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.240
- UV_RESPONSE_DN+0.140
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.130
- NOTCH_SIGNALING+0.120
- ESTROGEN_RESPONSE_LATE+0.110
- P53_PATHWAY+0.100
- MYOGENESIS+0.070
- BILE_ACID_METABOLISM+0.060
- APICAL_JUNCTION+0.030
- KRAS_SIGNALING_DN+0.020
Top 10 suppressed
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.550
- MTORC1_SIGNALING-0.470
- MYC_TARGETS_V1-0.470
- MYC_TARGETS_V2-0.450
- INTERFERON_GAMMA_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_ALPHA_RESPONSE-0.380
- IL6_JAK_STAT3_SIGNALING-0.370
- INFLAMMATORY_RESPONSE-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.918 |
| 2 | SRR1313097 | — | A | 0.891 |
| 3 | SRR8613701 | — | A | 0.879 |
| 4 | SRR8613714 | — | A | 0.877 |
| 5 | SRR5088900 | — | — | 0.873 |
| 6 | SRR1313093 | — | B | 0.871 |
| 7 | MBCProject_0814_T1_RNA | — | A | 0.866 |
| 8 | TCGA-A7-A5ZX-01A-12R-A29R-07 | — | A | 0.864 |
| 9 | s0122320 | — | — | 0.862 |
| 10 | TCGA-E2-A1BD-01A-11R-A12P-07 | — | B | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| MYOGENESIS | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |